Premium
Diabetes therapy‐focus on Asia: second‐line therapy debate: insulin/secretagogues
Author(s) -
Eldor Roy,
Raz Itamar
Publication year - 2012
Publication title -
diabetes/metabolism research and reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.307
H-Index - 110
eISSN - 1520-7560
pISSN - 1520-7552
DOI - 10.1002/dmrr.2358
Subject(s) - secretagogue , diabetes mellitus , medicine , insulin , china , focus (optics) , psychotherapist , political science , psychology , endocrinology , law , physics , optics
Summary The following review is based on the second part of a debate entitled ‘Diabetes therapy‐ focus on Asia: 2nd line therapy: GLP1/DPP4 inhibitors versus Secretagogue/insulin therapy’, which was held during the ‘1st Asia Pacific Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)’, in Shanghai, China, 2011. As such we reviewed only insulin and secretagogue therapy despite the existence of other therapeutic options. The article aims to shed light on the circumstances most adequate for use of these as second‐line agents, despite possible drawbacks. It is important to emphasize that regardless of it being a review of published evidence, it primarily represents the professional opinion of the writers.